Daiichi Sankyo posts 'extraordinary loss' of nearly $1B

Daiichi Sankyo is scrapping plans to build antibody-drug conjugate manufacturing capacity and recorded an "extraordinary loss" of 149.4 billion Japanese yen ($950 million) after overpromising demand for its ADCs to third-party manufacturers. The Japanese company ...